Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cation-transporting ATPase 4 (PfATP4) is an essential P-type ATPase located on the plasma membrane of the malaria parasite Plasmodium falciparum. It functions as a sodium-efflux pump, maintaining a low intracellular sodium concentration against the high sodium environment of the host's blood, which is vital for the parasite's osmotic stability and pH regulation. PfATP4 has emerged as a high-priority therapeutic target because it is inhibited by several chemically diverse classes of next-generation antimalarial compounds, including spiroindolones and aminobenzimidazoles. Inhibition of PfATP4 leads to a rapid and lethal influx of sodium ions into the parasite, resulting in cellular swelling and lysis. Because PfATP4 is structurally distinct from human ion pumps, it offers a high degree of selectivity and remains effective against parasite strains resistant to current frontline treatments like chloroquine and artemisinin.
Inhibition of PfATP4-mediated sodium efflux, leading to a rapid increase in intracellular sodium concentration, osmotic stress, and parasite death.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cation-transporting ATPase 4 (PfATP4) (PfATP4).